The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis

Inclusion Criteria: * patients with a diagnosis of FSGS. * Patients with a proteinuria ≥ 3.5g/24h,and blood albumin \<30g/L,and Scr\< 2.3 mg/dl and eGFR\>30ml/min per 1.73m2. * Patients who signed written informed consent form (patients less than 18 years old with their parents/legal representative's signatures), and have given their consent to follow all study procedures and follow-up. Exclusion Criteria: * Patients who have received treatment of FK506 in latest 2 month or the cumulative dose CTX≥6 g. * Patients who are known to be allergic to a macrolide. * Patients who have active hepatitis. * Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the normal upper limit . * Patients with blood leukocyte \< 3000/ul. * Patients with kidney disease family history * Patients with 2 type diabetes. * Patients with obesity whose BMI\>28kg/m2.